{"transactions":[{"id":701648,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-07-29T21:19:05.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":16700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":16700,"derivative":{"expiration_date":"2036-07-27","underlying":"Common Stock","underlying_shares":16700},"source":{"system":"sec-edgar","filing":"0001193125-26-324238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526324238/ownership.xml","form_type":"4"}},{"id":701647,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-29T21:19:05.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":25000,"derivative":{"exercise_price":6.18,"expiration_date":"2036-07-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-324238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526324238/ownership.xml","form_type":"4"}},{"id":734260,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-06-17T20:17:35.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":27881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service."}],"balance_after":27882,"derivative":{"underlying":"Common Stock","underlying_shares":27881},"source":{"system":"sec-edgar","filing":"0001405253-26-000013","document":"wk-form4_1781727451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000013/wk-form4_1781727451.xml","form_type":"4"}},{"id":734259,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-17T20:17:35.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":14396,"price":60.95,"value":877436.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":56801,"source":{"system":"sec-edgar","filing":"0001405253-26-000013","document":"wk-form4_1781727451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000013/wk-form4_1781727451.xml","form_type":"4"}},{"id":734258,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-17T20:17:35.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":27881,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":71197,"source":{"system":"sec-edgar","filing":"0001405253-26-000013","document":"wk-form4_1781727451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000013/wk-form4_1781727451.xml","form_type":"4"}},{"id":755832,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:12:33.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":47250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal monthly installments over 36 months commencing May 29, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":47250,"derivative":{"exercise_price":5.24,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":47250},"source":{"system":"sec-edgar","filing":"0001405253-26-000011","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000140525326000011/ownership.xml","form_type":"4"}},{"id":833574,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-19T23:03:53.000Z","date":"2026-03-19","kind":"sale","planned":false,"acquired":false,"shares":2186,"price":67,"value":146462.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":43316,"source":{"system":"sec-edgar","filing":"0001405253-26-000007","document":"wk-form4_1773961430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000007/wk-form4_1773961430.xml","form_type":"4"}},{"id":833573,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-19T23:03:53.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":2133,"price":68.71,"value":146558.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":45502,"source":{"system":"sec-edgar","filing":"0001405253-26-000007","document":"wk-form4_1773961430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000007/wk-form4_1773961430.xml","form_type":"4"}},{"id":833572,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-19T23:03:53.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":2111,"price":69.42,"value":146545.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":47635,"source":{"system":"sec-edgar","filing":"0001405253-26-000007","document":"wk-form4_1773961430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000007/wk-form4_1773961430.xml","form_type":"4"}},{"id":838208,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T20:27:01.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":5022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service."}],"balance_after":15067,"derivative":{"underlying":"Common Stock","underlying_shares":5022},"source":{"system":"sec-edgar","filing":"0001405253-26-000005","document":"wk-form4_1773779217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000005/wk-form4_1773779217.xml","form_type":"4"}},{"id":838207,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T20:27:01.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":8020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service."}],"balance_after":16040,"derivative":{"underlying":"Common Stock","underlying_shares":8020},"source":{"system":"sec-edgar","filing":"0001405253-26-000005","document":"wk-form4_1773779217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000005/wk-form4_1773779217.xml","form_type":"4"}},{"id":838206,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-17T20:27:01.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":13042,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."}],"balance_after":49746,"source":{"system":"sec-edgar","filing":"0001405253-26-000005","document":"wk-form4_1773779217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000005/wk-form4_1773779217.xml","form_type":"4"}},{"id":853673,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-03-09T20:06:51.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":19306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service."}],"balance_after":19306,"derivative":{"underlying":"Common Stock","underlying_shares":19306},"source":{"system":"sec-edgar","filing":"0001405253-26-000003","document":"wk-form4_1773086806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000003/wk-form4_1773086806.xml","form_type":"4"}},{"id":853672,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-09T20:06:51.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":30724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service."}],"balance_after":30724,"derivative":{"exercise_price":74.9,"expiration_date":"2036-03-04","underlying":"Common Stock","underlying_shares":30724},"source":{"system":"sec-edgar","filing":"0001405253-26-000003","document":"wk-form4_1773086806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000140525326000003/wk-form4_1773086806.xml","form_type":"4"}},{"id":1106433,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-06-18T20:07:59.000Z","date":"2025-06-16","kind":"exercise","planned":false,"acquired":false,"shares":27881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service."}],"balance_after":55763,"derivative":{"underlying":"Common Stock","underlying_shares":27881},"source":{"system":"sec-edgar","filing":"0001819790-25-000102","document":"wk-form4_1750277272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000102/wk-form4_1750277272.xml","form_type":"4"}},{"id":1106432,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-18T20:07:59.000Z","date":"2025-06-17","kind":"sale","planned":false,"acquired":false,"shares":13608,"price":40.42,"value":550035.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":36704,"source":{"system":"sec-edgar","filing":"0001819790-25-000102","document":"wk-form4_1750277272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000102/wk-form4_1750277272.xml","form_type":"4"}},{"id":1106431,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-18T20:07:59.000Z","date":"2025-06-16","kind":"exercise","planned":false,"acquired":true,"shares":27881,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":50312,"source":{"system":"sec-edgar","filing":"0001819790-25-000102","document":"wk-form4_1750277272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000102/wk-form4_1750277272.xml","form_type":"4"}},{"id":1195787,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-21T01:48:15.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":1186,"price":50.11,"value":59430.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":22431,"source":{"system":"sec-edgar","filing":"0001819790-25-000054","document":"wk-form4_1742521688.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000054/wk-form4_1742521688.xml","form_type":"4"}},{"id":1195786,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-21T01:48:15.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":1254,"price":47.4,"value":59439.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":23617,"source":{"system":"sec-edgar","filing":"0001819790-25-000054","document":"wk-form4_1742521688.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000054/wk-form4_1742521688.xml","form_type":"4"}},{"id":1195785,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-21T01:48:15.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":1284,"price":46.29,"value":59436.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":24871,"source":{"system":"sec-edgar","filing":"0001819790-25-000054","document":"wk-form4_1742521688.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000054/wk-form4_1742521688.xml","form_type":"4"}},{"id":1200214,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-03-19T01:40:39.000Z","date":"2025-03-17","kind":"exercise","planned":false,"acquired":false,"shares":8019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service."}],"balance_after":24060,"derivative":{"underlying":"Common Stock","underlying_shares":8019},"source":{"system":"sec-edgar","filing":"0001819790-25-000047","document":"wk-form4_1742348431.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000047/wk-form4_1742348431.xml","form_type":"4"}},{"id":1200213,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-19T01:40:39.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":true,"shares":8019,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."}],"balance_after":26155,"source":{"system":"sec-edgar","filing":"0001819790-25-000047","document":"wk-form4_1742348431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000047/wk-form4_1742348431.xml","form_type":"4"}},{"id":1217584,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-03-07T21:19:44.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":20089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service."}],"balance_after":20089,"derivative":{"underlying":"Common Stock","underlying_shares":20089},"source":{"system":"sec-edgar","filing":"0001819790-25-000027","document":"wk-form4_1741382377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000027/wk-form4_1741382377.xml","form_type":"4"}},{"id":1217583,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-07T21:19:44.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":30628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option  shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service."}],"balance_after":30628,"derivative":{"exercise_price":44.54,"expiration_date":"2035-03-04","underlying":"Common Stock","underlying_shares":30628},"source":{"system":"sec-edgar","filing":"0001819790-25-000027","document":"wk-form4_1741382377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000027/wk-form4_1741382377.xml","form_type":"4"}},{"id":1473336,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-06-20T20:26:33.000Z","date":"2024-06-17","kind":"exercise","planned":false,"acquired":false,"shares":27881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service."}],"balance_after":83644,"derivative":{"underlying":"Common Stock","underlying_shares":27881},"source":{"system":"sec-edgar","filing":"0001819790-24-000089","document":"wk-form4_1718915187.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000089/wk-form4_1718915187.xml","form_type":"4"}},{"id":1473335,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-06-20T20:26:33.000Z","date":"2024-06-18","kind":"sale","planned":false,"acquired":false,"shares":10445,"price":27.47,"value":286924.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":18136,"source":{"system":"sec-edgar","filing":"0001819790-24-000089","document":"wk-form4_1718915187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000089/wk-form4_1718915187.xml","form_type":"4"}},{"id":1473334,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-06-20T20:26:33.000Z","date":"2024-06-17","kind":"exercise","planned":false,"acquired":true,"shares":27881,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."}],"balance_after":28581,"source":{"system":"sec-edgar","filing":"0001819790-24-000089","document":"wk-form4_1718915187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000089/wk-form4_1718915187.xml","form_type":"4"}},{"id":1584373,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-03-11T21:11:36.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":32079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service."}],"balance_after":32079,"derivative":{"underlying":"Common Stock","underlying_shares":32079},"source":{"system":"sec-edgar","filing":"0001819790-24-000032","document":"wk-form4_1710191483.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000032/wk-form4_1710191483.xml","form_type":"4"}},{"id":1584372,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-11T21:11:36.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service."}],"balance_after":47500,"derivative":{"exercise_price":35.5,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001819790-24-000032","document":"wk-form4_1710191483.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000032/wk-form4_1710191483.xml","form_type":"4"}},{"id":1913394,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-04-26T21:05:03.000Z","date":"2023-04-24","kind":"grant","planned":false,"acquired":true,"shares":111525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service."}],"balance_after":111525,"derivative":{"underlying":"Common Stock","underlying_shares":111525},"source":{"system":"sec-edgar","filing":"0001819790-23-000020","document":"wf-form4_168254308276163.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000020/wf-form4_168254308276163.xml","form_type":"4"}},{"id":1913393,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-26T21:05:03.000Z","date":"2023-04-24","kind":"grant","planned":false,"acquired":true,"shares":163397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares shall vest on April 24, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service."}],"balance_after":163397,"derivative":{"exercise_price":14.62,"expiration_date":"2033-04-23","underlying":"Common Stock","underlying_shares":163397},"source":{"system":"sec-edgar","filing":"0001819790-23-000020","document":"wf-form4_168254308276163.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000020/wf-form4_168254308276163.xml","form_type":"4"}},{"id":2141211,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":28628,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":29.87,"underlying":"Common Stock","underlying_shares":28628},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141210,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":38739,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":44.48,"underlying":"Common Stock","underlying_shares":38739},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141209,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":38500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":65.82,"underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141208,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":48.44,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141207,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":59.6,"underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141206,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":10299,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":16.4,"underlying":"Common Stock","underlying_shares":10299},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141205,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":14.96,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141204,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":42400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42400},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141203,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":26454,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26454},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141202,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15460,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15460},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141201,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":13814,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13814},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141200,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":9060,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9060},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141199,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":3125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2141198,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-06T20:15:25.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":26739,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322033145/doc4.xml","form_type":"4"}},{"id":2149375,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-30T00:48:26.000Z","date":"2022-09-27","kind":"exercise","acquired":false,"shares":23653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying the option vested in equal quarterly installments over 16 quarters from January 17, 2017 through January 17, 2021."}],"balance_after":10299,"derivative":{"exercise_price":16.4,"expiration_date":"2027-01-16","underlying":"Common Stock","underlying_shares":23653},"source":{"system":"sec-edgar","filing":"0000899243-22-032265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322032265/doc4.xml","form_type":"4"}},{"id":2149374,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-30T00:48:26.000Z","date":"2022-09-27","kind":"exercise","acquired":true,"shares":23653,"price":16.4,"value":387909.2,"ownership":{"direct":true},"balance_after":26739,"source":{"system":"sec-edgar","filing":"0000899243-22-032265","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322032265/doc4.xml","form_type":"4"}},{"id":2165426,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T23:00:22.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":2208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15460,"derivative":{"underlying":"Common Stock","underlying_shares":2208},"source":{"system":"sec-edgar","filing":"0000899243-22-030475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322030475/doc4.xml","form_type":"4"}},{"id":2165425,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T23:00:22.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":13814,"derivative":{"underlying":"Common Stock","underlying_shares":2763},"source":{"system":"sec-edgar","filing":"0000899243-22-030475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322030475/doc4.xml","form_type":"4"}},{"id":2165424,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:22.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":31441,"price":68,"value":2137988.0,"ownership":{"direct":true},"balance_after":3086,"source":{"system":"sec-edgar","filing":"0000899243-22-030475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322030475/doc4.xml","form_type":"4"}},{"id":2165423,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:22.000Z","date":"2022-09-01","kind":"tax_withholding","acquired":false,"shares":1885,"price":68.15,"value":128462.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,971 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":34527,"source":{"system":"sec-edgar","filing":"0000899243-22-030475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322030475/doc4.xml","form_type":"4"}},{"id":2165422,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:22.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":2208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":36412,"source":{"system":"sec-edgar","filing":"0000899243-22-030475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322030475/doc4.xml","form_type":"4"}},{"id":2165421,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T23:00:22.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":2763,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":34204,"source":{"system":"sec-edgar","filing":"0000899243-22-030475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322030475/doc4.xml","form_type":"4"}},{"id":2195545,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-03T22:00:53.000Z","date":"2022-08-01","kind":"exercise","acquired":false,"shares":3020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":9060,"derivative":{"underlying":"Common Stock","underlying_shares":3020},"source":{"system":"sec-edgar","filing":"0000899243-22-027634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322027634/doc4.xml","form_type":"4"}},{"id":2195544,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-03T22:00:53.000Z","date":"2022-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":3125,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-22-027634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322027634/doc4.xml","form_type":"4"}},{"id":2195543,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-03T22:00:53.000Z","date":"2022-08-01","kind":"tax_withholding","acquired":false,"shares":2126,"price":32.4,"value":68882.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,145 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":31441,"source":{"system":"sec-edgar","filing":"0000899243-22-027634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322027634/doc4.xml","form_type":"4"}},{"id":2195542,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-03T22:00:53.000Z","date":"2022-08-01","kind":"exercise","acquired":true,"shares":6145,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":33567,"source":{"system":"sec-edgar","filing":"0000899243-22-027634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322027634/doc4.xml","form_type":"4"}},{"id":2353744,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2022-03-04T01:52:52.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":28628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":28628,"derivative":{"exercise_price":29.87,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":28628},"source":{"system":"sec-edgar","filing":"0000899243-22-009239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322009239/doc4.xml","form_type":"4"}},{"id":2353743,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T01:52:52.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":17668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17668,"derivative":{"underlying":"Common Stock","underlying_shares":17668},"source":{"system":"sec-edgar","filing":"0000899243-22-009239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322009239/doc4.xml","form_type":"4"}},{"id":2353742,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T01:52:52.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":17668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17668,"derivative":{"underlying":"Common Stock","underlying_shares":17668},"source":{"system":"sec-edgar","filing":"0000899243-22-009239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322009239/doc4.xml","form_type":"4"}},{"id":2353741,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T01:52:52.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":16577,"derivative":{"underlying":"Common Stock","underlying_shares":2763},"source":{"system":"sec-edgar","filing":"0000899243-22-009239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322009239/doc4.xml","form_type":"4"}},{"id":2353740,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-04T01:52:52.000Z","date":"2022-03-01","kind":"tax_withholding","acquired":false,"shares":1315,"price":29.87,"value":39279.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,763 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":27422,"source":{"system":"sec-edgar","filing":"0000899243-22-009239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322009239/doc4.xml","form_type":"4"}},{"id":2353739,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-04T01:52:52.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":2763,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":28737,"source":{"system":"sec-edgar","filing":"0000899243-22-009239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322009239/doc4.xml","form_type":"4"}},{"id":2413485,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T22:49:12.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":3020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":12080,"derivative":{"underlying":"Common Stock","underlying_shares":3020},"source":{"system":"sec-edgar","filing":"0000899243-22-004639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322004639/doc4.xml","form_type":"4"}},{"id":2413484,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T22:49:12.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":6250,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-22-004639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322004639/doc4.xml","form_type":"4"}},{"id":2413483,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T22:49:12.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0000899243-22-004639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322004639/doc4.xml","form_type":"4"}},{"id":2413482,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-03T22:49:12.000Z","date":"2022-02-01","kind":"tax_withholding","acquired":false,"shares":4506,"price":29.33,"value":132160.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,020 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":25974,"source":{"system":"sec-edgar","filing":"0000899243-22-004639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322004639/doc4.xml","form_type":"4"}},{"id":2413481,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-03T22:49:12.000Z","date":"2022-02-01","kind":"exercise","acquired":true,"shares":9020,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30480,"source":{"system":"sec-edgar","filing":"0000899243-22-004639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924322004639/doc4.xml","form_type":"4"}},{"id":2559792,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T23:00:23.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15100,"derivative":{"underlying":"Common Stock","underlying_shares":3020},"source":{"system":"sec-edgar","filing":"0000899243-21-037668","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321037668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559791,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T23:00:23.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":9375,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-21-037668","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321037668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559790,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T23:00:23.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":2875,"derivative":{"underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0000899243-21-037668","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321037668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559789,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-24T23:00:23.000Z","date":"2021-08-01","kind":"tax_withholding","acquired":false,"shares":4354,"price":27.33,"value":118994.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,020 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":20068,"source":{"system":"sec-edgar","filing":"0000899243-21-037668","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321037668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559788,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-24T23:00:23.000Z","date":"2021-08-01","kind":"exercise","acquired":true,"shares":9020,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":24422,"source":{"system":"sec-edgar","filing":"0000899243-21-037668","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321037668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2578982,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-04T00:00:44.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":2762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":19340,"derivative":{"underlying":"Common Stock","underlying_shares":2762},"source":{"system":"sec-edgar","filing":"0000899243-21-035221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321035221/doc4.xml","form_type":"4"}},{"id":2578981,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-04T00:00:44.000Z","date":"2021-09-01","kind":"tax_withholding","acquired":false,"shares":1370,"price":29.85,"value":40894.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,762 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":21460,"source":{"system":"sec-edgar","filing":"0000899243-21-035221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321035221/doc4.xml","form_type":"4"}},{"id":2578980,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-04T00:00:44.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":2762,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":22830,"source":{"system":"sec-edgar","filing":"0000899243-21-035221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321035221/doc4.xml","form_type":"4"}},{"id":2617410,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T22:19:58.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15100,"derivative":{"underlying":"Common Stock","underlying_shares":3020},"source":{"system":"sec-edgar","filing":"0000899243-21-031353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321031353/doc4.xml","form_type":"4"}},{"id":2617409,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T22:19:58.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":9375,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-21-031353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321031353/doc4.xml","form_type":"4"}},{"id":2617408,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T22:19:58.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":2875,"derivative":{"underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0000899243-21-031353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321031353/doc4.xml","form_type":"4"}},{"id":2617407,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-03T22:19:58.000Z","date":"2021-08-01","kind":"tax_withholding","acquired":false,"shares":4354,"price":27.33,"value":118994.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,020 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":20068,"source":{"system":"sec-edgar","filing":"0000899243-21-031353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321031353/doc4.xml","form_type":"4"}},{"id":2617406,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-03T22:19:58.000Z","date":"2021-08-01","kind":"exercise","acquired":true,"shares":9020,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":24422,"source":{"system":"sec-edgar","filing":"0000899243-21-031353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321031353/doc4.xml","form_type":"4"}},{"id":2812560,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-04T00:32:30.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":22102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":22102,"derivative":{"underlying":"Common Stock","underlying_shares":22102},"source":{"system":"sec-edgar","filing":"0000899243-21-009542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321009542/doc4.xml","form_type":"4"}},{"id":2812559,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T00:32:30.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":38739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":38739,"derivative":{"exercise_price":44.48,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":38739},"source":{"system":"sec-edgar","filing":"0000899243-21-009542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321009542/doc4.xml","form_type":"4"}},{"id":2881409,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:14:00.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":18120,"derivative":{"underlying":"Common Stock","underlying_shares":3020},"source":{"system":"sec-edgar","filing":"0000899243-21-004760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321004760/doc4.xml","form_type":"4"}},{"id":2881408,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:14:00.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-21-004760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321004760/doc4.xml","form_type":"4"}},{"id":2881407,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:14:00.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each \tvesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each \tvesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":5750,"derivative":{"underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0000899243-21-004760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321004760/doc4.xml","form_type":"4"}},{"id":2881406,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-04T00:14:00.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3063},"source":{"system":"sec-edgar","filing":"0000899243-21-004760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321004760/doc4.xml","form_type":"4"}},{"id":2881405,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:14:00.000Z","date":"2021-02-01","kind":"tax_withholding","acquired":false,"shares":5865,"price":49.49,"value":290258.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 12,083 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":15402,"source":{"system":"sec-edgar","filing":"0000899243-21-004760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321004760/doc4.xml","form_type":"4"}},{"id":2881404,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:14:00.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":12083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":21267,"source":{"system":"sec-edgar","filing":"0000899243-21-004760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924321004760/doc4.xml","form_type":"4"}},{"id":3069385,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-05T01:26:01.000Z","date":"2020-08-01","kind":"exercise","acquired":false,"shares":3020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":21140,"derivative":{"underlying":"Common Stock","underlying_shares":3020},"source":{"system":"sec-edgar","filing":"0000899243-20-021323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320021323/doc4.xml","form_type":"4"}},{"id":3069384,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-05T01:26:01.000Z","date":"2020-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15625,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-20-021323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320021323/doc4.xml","form_type":"4"}},{"id":3069383,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-05T01:26:01.000Z","date":"2020-08-01","kind":"exercise","acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":8625,"derivative":{"underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0000899243-20-021323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320021323/doc4.xml","form_type":"4"}},{"id":3069382,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-05T01:26:01.000Z","date":"2020-08-01","kind":"exercise","acquired":false,"shares":3062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":3063,"derivative":{"underlying":"Common Stock","underlying_shares":3062},"source":{"system":"sec-edgar","filing":"0000899243-20-021323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320021323/doc4.xml","form_type":"4"}},{"id":3069381,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-05T01:26:01.000Z","date":"2020-08-01","kind":"tax_withholding","acquired":false,"shares":5946,"price":67.48,"value":401236.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 12,082 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":9184,"source":{"system":"sec-edgar","filing":"0000899243-20-021323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320021323/doc4.xml","form_type":"4"}},{"id":3069380,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-05T01:26:01.000Z","date":"2020-08-01","kind":"exercise","acquired":true,"shares":12082,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15130,"source":{"system":"sec-edgar","filing":"0000899243-20-021323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320021323/doc4.xml","form_type":"4"}},{"id":3082550,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-07-15T21:11:41.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":15208,"price":75,"value":1140600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2020."}],"balance_after":3048,"source":{"system":"sec-edgar","filing":"0000899243-20-019186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320019186/doc4.xml","form_type":"4"}},{"id":3113232,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-11T20:06:11.000Z","date":"2020-06-09","kind":"sale","acquired":false,"shares":15208,"price":67,"value":1018936.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2020."}],"balance_after":18256,"source":{"system":"sec-edgar","filing":"0000899243-20-016154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320016154/doc4.xml","form_type":"4"}},{"id":3123734,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-06-03T23:52:30.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":42400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":42400,"derivative":{"underlying":"Common Stock","underlying_shares":42400},"source":{"system":"sec-edgar","filing":"0000899243-20-015158","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320015158/doc4.xml","form_type":"4"}},{"id":3291282,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-05T01:18:18.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":38500,"derivative":{"exercise_price":65.82,"expiration_date":"2030-02-02","underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0000899243-20-002967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320002967/doc4.xml","form_type":"4"}},{"id":3291281,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":28092,"kind":"person","name":"Farrow Jeffrey S","position":1,"cik":"0001405253","reported_name":"Farrow Jeffrey S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-05T01:18:18.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":24160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":24160,"derivative":{"underlying":"Common Stock","underlying_shares":24160},"source":{"system":"sec-edgar","filing":"0000899243-20-002967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1405253/000089924320002967/doc4.xml","form_type":"4"}}],"next_cursor":"2020-02-05T01:18:18.000000Z,3291281"}